Clinical reference Biomarker Directory
Back to directory

LPL

Emerging

LPL deficiency causes familial chylomicronemia syndrome, now treatable with a December 2024 FDA-approved antisense drug (olezarsen).

Also known as LPL lipoprotein lipase deficiency
In plain language

LPL breaks down fat in the blood. When it's missing, triglycerides can rise to dangerous levels and cause repeated, serious pancreas inflammation. A new drug approved in December 2024 works around this missing enzyme by targeting a different part of the same fat-processing pathway.

Biomarker & context

Lipoprotein lipase (LPL) is an enzyme that breaks down triglycerides in circulating lipoproteins, allowing fatty acid uptake by tissues; its deficiency causes a rare, severe form of hypertriglyceridemia.

What it indicates

LPL deficiency causes familial chylomicronemia syndrome (FCS), characterized by extremely high triglycerides and recurrent, potentially fatal acute pancreatitis, distinct from more common, milder forms of hypertriglyceridemia.

Diagnosis & clinical testing

Diagnosed via genetic testing (LPL gene sequencing) combined with markedly elevated fasting triglycerides (often >1,000 mg/dL) and a compatible clinical history of recurrent pancreatitis episodes triggered by dietary fat.

Guiding treatment

Olezarsen (Tryngolza) was FDA-approved in December 2024 — an antisense drug that lowers apoC-III to indirectly boost the triglyceride-clearing pathway that LPL deficiency disrupts, joining the earlier-approved volanesorsen as a real treatment option for a condition that had none beyond severe dietary fat restriction for decades.

Clinical significance

Represents a rare condition with a genuinely new treatment option after decades of dietary restriction being the only management.

References
  1. FDA. (2024). Olezarsen (Tryngolza) Approval for Familial Chylomicronemia Syndrome.